Hwail Pharm Director Jang Sun-ho Shareholding Reduced Due to Stock Merger, Neutral Impact on Shareholder Value

Hwail Pharm's non-registered director Jang Sun-ho disclosed via a major shareholder ownership report that his shareholding decreased from 36,251 shares to 3,625 shares due to a stock merger.
This change occurred on April 9, 2026, due to a stock merger, and his ownership ratio slightly declined from 0.05% to 0.04%.
This disclosure is a routine corporate action, not a capital raising or convertible bond issuance, thus limited direct impact on shareholder value.
The company did not disclose any treasury stock acquisition, cancellation, or dividend payments.
[AI Summary]This is a routine stock merger adjustment for a non-registered director with no new funding or management change, resulting in a neutral impact on enterprise value and stock price. No significant risk for investors.